Ketamine Treatment for Depression in Missouri
Two related medicines are discussed for depression, and they are not interchangeable: FDA-approved esketamine (Spravato) under a REMS programme, and off-label racemic ketamine usually given as an infusion. What follows is what the evidence and labels actually say — not a promise that either will work for you.
Direct answer
The FDA approved Spravato (esketamine) nasal spray on 5 March 2019, for use with an oral antidepressant, for adults with treatment-resistant depression. as of 5 Mar 2019 · U.S. Food and Drug Administration (source 1, opens in a new tab)
On 17 January 2025 the FDA approved Spravato for treatment-resistant depression in adults either on its own or together with an oral antidepressant, so a companion oral antidepressant is now optional for this use — though it is still permitted. as of 17 Jan 2025 · U.S. Food and Drug Administration (source 2, opens in a new tab)This applies to the treatment-resistant depression indication only. The separate indication for major depressive disorder with acute suicidal ideation still requires an oral antidepressant — see spravato.approval_mdd_si. Widely-cited secondary sources give 21 January 2025; that is the manufacturer's announcement date, not the FDA action date on the approval letter.
Only esketamine (Spravato) is FDA-approved to treat depression. Racemic ketamine given by IV, injection, or under the tongue has no FDA approval for any psychiatric condition and is used off-label — that is, an approved drug used for an unapproved purpose. as of 30 Apr 2025 · U.S. Food and Drug Administration (source 1, opens in a new tab)
Randomised trials and systematic reviews report that a single sub-anaesthetic intravenous infusion of racemic ketamine can reduce depressive symptoms within hours in some adults with major depression or treatment-resistant depression, but the effect often fades within days to a week without a maintenance strategy, and racemic ketamine has no FDA psychiatric indication. as of 1 Apr 2019 · American Journal of Psychiatry / PubMed (source 1, opens in a new tab)This is research evidence, not an FDA approval. Off-label use remains lawful medical practice when a licensed clinician judges it appropriate.
What “treatment-resistant depression” means here
Treatment-resistant depression usually means major depression that has not improved after at least two different antidepressant medicines taken at an adequate dose for long enough — often about six to eight weeks each — though exact definitions vary by study and by insurer. as of 30 Apr 2025 · U.S. Food and Drug Administration (source 3, opens in a new tab)Commercial payers and state Medicaid programmes each publish their own prior-authorisation wording; the clinical definition and the coverage definition are not always identical.
If you are earlier in treatment — one medicine tried, or none — first-line options and psychotherapy still come first for most people. Ketamine-class treatments are generally discussed after standard approaches have not been enough, except in carefully selected acute situations under specialist care.
What the Spravato trials showed
In the pivotal short-term trials that supported FDA approval, adults with treatment-resistant depression who received Spravato with an oral antidepressant improved more on the Montgomery–Åsberg Depression Rating Scale than those who received a placebo nasal spray with an oral antidepressant. as of 30 Apr 2025 · U.S. Food and Drug Administration (source 5, opens in a new tab)Trial populations are selected, monitoring is intensive, and individual response cannot be predicted from group averages.
On 31 July 2020 the FDA separately approved Spravato, used together with an oral antidepressant, for depressive symptoms in adults who have major depressive disorder with acute suicidal thoughts or behaviour; for this use the oral antidepressant is still required, and it is not a substitute for hospital care when hospital care is needed. as of 31 Jul 2020 · U.S. Food and Drug Administration (source 4, opens in a new tab)
Those results come from monitored clinical trial settings with strict entry criteria. Real-world clinics vary. Nobody can honestly quote you a personal probability of remission from a marketing page.
Racemic (IV) ketamine — research use, not an FDA depression drug
Randomised trials and systematic reviews report that a single sub-anaesthetic intravenous infusion of racemic ketamine can reduce depressive symptoms within hours in some adults with major depression or treatment-resistant depression, but the effect often fades within days to a week without a maintenance strategy, and racemic ketamine has no FDA psychiatric indication. as of 1 Apr 2019 · American Journal of Psychiatry / PubMed (source 1, opens in a new tab)This is research evidence, not an FDA approval. Off-label use remains lawful medical practice when a licensed clinician judges it appropriate.
UnitedHealthcare's national policy states that ketamine injection is investigational, and therefore not proven or medically necessary, for psychiatric conditions including depression, bipolar disorder and post-traumatic stress disorder. This is the clearest published statement of why commercial insurance rarely pays for IV ketamine. as of 1 May 2026 · UnitedHealthcare (source 8, opens in a new tab)This describes one commercial insurer. It does not describe any state Medicaid programme, none of which publishes criteria for racemic ketamine either way.
Off-label prescribing is lawful medical practice in the United States when a licensed clinician judges it appropriate. Lawful is not the same as “usually paid for by insurance,” and it is not the same as “proven for your exact situation.”
Oral and at-home routes
Compounded lozenges and telehealth programmes market heavily to people searching for depression help. Bioavailability, dose consistency and monitoring all differ from clinic administration. Read the monitoring gap on the safety page before treating a mail-order kit as equivalent to a REMS session.
At-home and microdosing ketamine programmes remove the on-site monitoring that clinic protocols use to catch blood-pressure spikes, severe dissociation, sedation and diversion — so the convenience trade-off is a real safety gap, not a minor difference in setting. as of 30 Apr 2025 · U.S. Food and Drug Administration (source 1, opens in a new tab)Spravato cannot be taken at home under the REMS. Compounded at-home racemic products are a different regulatory pathway and are not REMS-certified substitutes.
MO HealthNet: treatment-resistant depression and Spravato
MO HealthNet, Missouri's Medicaid programme, covers Spravato but applies a clinical edit requiring prior approval, and the medicine must be given at a treatment centre certified in the Spravato REMS programme. as of 21 Jul 2022 · Missouri Department of Social Services, MO HealthNet Division (source 5, opens in a new tab)The published criteria document dates from 2022 and a newer revision may exist that we could not retrieve. Ask your clinic to confirm the current requirements before you rely on these details.
MO HealthNet's Spravato criteria — clinical edit 0682 — approve only four weeks at first, and require documented failure of at least two antidepressants from different groups, each for six weeks or more, with less than a 50% improvement on a recognised depression scale. On top of that they require a six-week trial of add-on treatment, which can mean an antipsychotic, lithium, a different antidepressant, electroconvulsive therapy or transcranial magnetic stimulation. The prescriber must also confirm that a REMS-certified centre you can actually reach has been identified. as of 21 Jul 2022 · Missouri Department of Social Services, MO HealthNet Division (source 5, opens in a new tab)The add-on trial requirement is the hardest barrier here and is the one most often left out of summaries. Note also that this 2022 document still requires a companion oral antidepressant, which predates the FDA's January 2025 monotherapy approval — it may since have been revised, so confirm the current rule.
MO HealthNet drug criteria and preferred-drug information
Commercial plans in Missouri are summarised on the insurance page, including the manufacturer copay programme and its government-insurance exclusion.
Safety context for depression treatment
In treatment-resistant depression studies the most common side effects of Spravato were dissociation, dizziness, nausea, sedation, vertigo, reduced sense of touch, anxiety, lethargy, increased blood pressure, vomiting, feeling drunk, and headache. as of 30 Apr 2025 · U.S. Food and Drug Administration (source 11, opens in a new tab)The label lists a different set for the major-depressive-disorder-with-acute-suicidality indication. The two lists should not be conflated.
Spravato carries a boxed warning for sedation, dissociation, respiratory depression, abuse and misuse, and suicidal thoughts and behaviours — the same class of risks that justify the REMS clinic-only distribution system. as of 30 Apr 2025 · U.S. Food and Drug Administration (source 9, opens in a new tab)
Depression itself carries suicide risk. Starting or changing any intensive treatment is a period for closer support, not less. If thoughts of suicide intensify, contact your clinician or use crisis resources immediately.
If you are in crisis, call or text 988 to reach the 988 Suicide & Crisis Lifeline, or text HOME to 741741 to reach the Crisis Text Line. Both are free and available 24 hours a day. as of 18 Jul 2026 · 988 Suicide and Crisis Lifeline (source 1, opens in a new tab)